This page provides a comprehensive comparison of leading Brain-Computer Interface (BCI) companies, covering their technology, FDA status, and primary applications. This includes both emerging BCI companies developing novel neural interfaces and established neuromodulation companies with FDA-approved deep brain stimulation (DBS) and responsive neurostimulation (RNS) systems.
| Company |
Electrode Count |
Bandwidth |
Latency |
Invasiveness |
FDA Status |
Primary Application |
Funding |
| Neuralink |
~1,024 |
High |
<20ms |
Invasive (64-thread implant) |
FDA Breakthrough Device (human trials) |
Quadriplegia, blindness |
~$280M |
| Blackrock Neurotech |
1,000+ |
Very High |
<10ms |
Invasive (Utah Array) |
FDA approved (clinical use) |
Neuroscience research, ALS |
~$30M |
| Paradromics |
65,000+ |
Very High |
<20ms |
Invasive (Utah Array) |
FDA Breakthrough Device |
Communication for paralyzed patients |
~$60M |
| BrainGate |
96-128 |
Very High |
<20ms |
Invasive (Utah Array) |
Clinical trials |
Quadriplegia, ALS |
Research funded |
| Company |
Electrode Count |
Bandwidth |
Latency |
Invasiveness |
FDA Status |
Primary Application |
Patients Treated |
| Medtronic |
4-8 |
High |
<50ms |
Invasive (DBS implant) |
FDA Approved (1997) |
Parkinson's, essential tremor |
150,000+ |
| Abbott Laboratories |
8 |
High |
<50ms |
Invasive (Infinity DBS) |
FDA Approved (2016) |
Parkinson's disease |
20,000+ |
| Boston Scientific |
8 |
High |
<50ms |
Invasive (Vercise DBS) |
FDA Approved (2017) |
Parkinson's disease |
10,000+ |
| NeuroPace |
4-8 |
Medium |
<100ms |
Invasive (RNS implant) |
FDA Approved (2013) |
Epilepsy |
5,000+ |
| Company |
Electrode Count |
Bandwidth |
Latency |
Invasiveness |
FDA Status |
Primary Application |
Funding |
| Synchron |
16 |
Medium |
<100ms |
Minimally invasive (stentrode) |
FDA IDE (Investigational Device Exemption) approved |
Paralysis, ALS |
~$60M |
| Precision Neuroscience |
1,024+ |
High |
<20ms |
Minimally invasive (Layer 7) |
FDA Breakthrough Device |
Memory, vision restoration |
~$70M |
| Science Corp |
1,024+ |
High |
<20ms |
Minimally invasive (optic nerve) |
Pre-clinical |
Vision restoration |
Seed |
| Motif Neurotech |
64-256 |
Medium |
<50ms |
Minimally invasive (piston implant) |
Pre-clinical |
Memory augmentation |
~$10M |
| Forest Neurotech |
100+ |
High |
<20ms |
Minimally invasive (thin-film) |
Pre-clinical |
Neural recording |
~$5M |
| Company |
Electrode Count |
Bandwidth |
Latency |
Invasiveness |
FDA Status |
Primary Application |
Funding |
| Kernel |
1,000+ |
High |
<50ms |
Non-invasive (helmets) |
R&D |
Neuroscience research |
~$10M |
| MindMaze |
64+ |
Medium-High |
<30ms |
Non-invasive (VR+EEG) |
FDA cleared (rehabilitation) |
Stroke rehab, VR |
~$185M |
| g.tec |
64-256 |
High |
<20ms |
Non-invasive (EEG caps) |
FDA cleared |
Neuroscience research, BCI |
~$15M |
| EMOTIV |
32-64 |
Medium |
<50ms |
Non-invasive (EEG headset) |
FDA cleared |
Consumer BCI, research |
~$20M |
| Bitbrain |
32-64 |
Medium |
<50ms |
Non-invasive (EEG wearables) |
FDA cleared |
Health monitoring, attention |
~$20M |
| Neurable |
8-32 |
Low-Medium |
<100ms |
Non-invasive (headset) |
Product development |
Gaming, productivity |
~$12M |
| Cognixion |
64+ |
Medium |
<50ms |
Non-invasive (EEG+AR) |
FDA Breakthrough Device |
Communication for AAC |
~$21M |
| BrainCo |
16-64 |
Medium |
<50ms |
Non-invasive (EEG headband) |
FDA cleared |
Focus training, HFOs |
~$20M |
| CTRL-Labs |
8-16 |
Medium |
<50ms |
Non-invasive (wrist EMG) |
Acquired (Meta 2019) |
AR/VR control |
$500M-$1B |
| NextMind |
8-16 |
Low-Medium |
<100ms |
Non-invasive (EEG headband) |
Acquired (Snap 2023) |
Visual attention, gaming |
Seed |
Emerging Invasive BCI (high bandwidth, novel implants):
- Neuralink: 64 threads with 1,024 electrodes each, wireless transmission, fully implantable
- Blackrock Neurotech: Utah Array platform with established clinical history
- Paradromics: High-density 65,000+ electrode array, first patient implanted in 2024
- BrainGate: Academic-clinical consortium, 96-128 electrode arrays, decades of clinical data
Established Neuromodulation (FDA-approved DBS/RNS):
- Medtronic: Pioneer in DBS since 1997, Activa PC/RC neurostimulators, 150,000+ patients treated worldwide, established safety profile
- Abbott Laboratories: Infinity DBS system acquired via St. Jude Medical merger (2016), smallest IPG, directional leads, 20,000+ patients
- Boston Scientific: Vercise DBS systems (FDA approved 2017/2020), AI-powered Neural Navigator programming, INTREPID trial data
- NeuroPace: Responsive Neurostimulation (RNS) system for epilepsy, FDA approved 2013, first closed-loop epilepsy device, 5,000+ implants
Minimally Invasive (endovascular or thin-film):
- Synchron: Stentrode placed via jugular vein, motor imagery control
- Precision Neuroscience: Layer 7 cortical interface, micro-electrode array
- Science Corp: Blindsight system targeting optic nerve for vision restoration
- Motif Neurotech: Piston-style implant for memory augmentation
- Forest Neurotech: Thin-film arrays for chronic recording
Non-Invasive (wearables, no surgery):
- Kernel: Flow and Flux helmets using fNIRS/MEG technologies
- MindMaze: VR-based neurorehabilitation platform with EEG
- g.tec: High-end research EEG systems with g.NAmp amplifiers
- EMOTIV: Consumer-grade EPOC headsets for BCI applications
- Bitbrain: Wearable EEG for health monitoring and cognitive assessment
- Neurable: Direct neural control for gaming and productivity
- Cognixion: OneSpeak AAC system combining EEG with AR interface
- BrainCo: Focus headband and BrainCo OS platform
- CTRL-Labs: Wrist-worn EMG interface (acquired by Meta), decodes muscle signals before physical movement
- NextMind: EEG-based visual attention decoding (acquired by Snap), real-time cognitive state analysis
| Status |
Companies |
| FDA Approved (clinical use) |
Blackrock Neurotech, Medtronic, Abbott, Boston Scientific, NeuroPace |
| FDA Cleared |
MindMaze, g.tec, EMOTIV, Bitbrain, BrainCo |
| Human Trials |
Neuralink, Synchron, Paradromics, BrainGate |
| FDA Breakthrough Device |
Precision Neuroscience, Cognixion |
| Pre-clinical |
Science Corp, Motif Neurotech, Forest Neurotech |
| R&D |
Kernel, Neurable |
| Acquired (Active Development) |
CTRL-Labs (Meta), NextMind (Snap) |
Neuralink PRIME Study (NCT05126784)
- First human implant (January 2025): Patient demonstrated ability to control computer cursor, play chess, and interact with software using neural signals
- Signal quality: 1,024 electrodes recording from motor cortex
- Performance: High-accuracy motor intent decoding (>90% accuracy for cursor movement)
- Safety: No serious adverse events reported in initial cohort
Blackrock Neurotech MoveAgain BCI (FDA Approved 2025)
- Utah Array clinical use: Established safety profile with >15 years of clinical data
- Published outcomes: Willett et al. (2021) demonstrated high-performance handwriting communication at 90+ characters per minute
- Patients treated: Multiple clinical centers worldwide using Blackrock systems
Synchron COMMAND Trial (NCT05038382)
- Completed enrollment: 6 patients with severe paralysis
- Primary endpoint: Motor function improvement and device safety
- Results: Stentrode successfully enabled motor imagery control of external devices
- FDA approval expected: 2026
Paradromics CONCEPT Trial (NCT05823786)
- First human implant: 2024
- Device: Connexus Direct Data Interface with 65,000+ electrodes
- Target: High-bandwidth communication for paralyzed patients
Medtronic DBS for Parkinson's Disease
- Long-term outcomes: STING-AD and EARLYSTIM trials demonstrate significant motor symptom improvement (40-60% reduction in OFF medication time)
- Patients treated: >150,000 worldwide since 1997
- Quality of life: PDQ-39 improvement of 20-30% in treated patients
Boston Scientific INTREPID Trial (NCT02302178)
- Double-blind randomized controlled trial
- Results: 46% improvement in motor scores vs. sham
- FDA approval: 2020 for Vercise DBS system
Abbott Infinity DBS SYSTEM
- Clinical evidence: THUNDER trial demonstrated comparable outcomes to Medtronic
- Advantage: Directional leads reduce side effects by 50%
NeuroPace RNS for Epilepsy
- SANTE Trial (NCT00572195): 29% reduction in seizure frequency at 2 years, 50%+ reduction at 5 years
- Patients: >5,000 implants since FDA approval in 2013
- First closed-loop neurostimulation system
MindMaze Stroke Rehabilitation
- FDA Cleared: 2021 for neurorehabilitation
- Clinical trials: Multiple RCTs demonstrating improved motor recovery vs. standard therapy
- Outcomes: 20-30% improvement in Fugl-Meyer Assessment scores
g.tec EEG-Based Communication
- Clinical use: Research and clinical applications for locked-in syndrome
- Performance: P300 speller achieving 70-90% accuracy in spelling tasks
Cognixion OneSpeak (FDA Breakthrough Device)
- Target: AAC communication for ALS and cerebral palsy
- Clinical trials: Ongoing for communication accuracy and speed
| Technology |
Evidence Level |
Key Studies |
Outcomes |
| Medtronic DBS |
Level I (RCT) |
STING-AD, EARLYSTIST |
40-60% motor improvement |
| Boston Scientific DBS |
Level I (RCT) |
INTREPID |
46% motor improvement |
| NeuroPace RNS |
Level I (RCT) |
SANTE |
29-50% seizure reduction |
| Blackrock Utah Array |
Level II-III |
Multiple cohort studies |
High-bandwidth decoding |
| Synchron Stentrode |
Level II |
COMMAND Trial |
Motor imagery control |
| Neuralink |
Level II |
PRIME Study |
High-accuracy cursor control |
| MindMaze |
Level I (RCT) |
Multiple trials |
20-30% motor improvement |
| BCI Spelling |
Level II-III |
Multiple studies |
70-90% accuracy |
¶ Market Landscape
The BCI market is rapidly evolving with significant investment flowing into both invasive and non-invasive approaches. The market includes two distinct segments: emerging BCI companies developing novel neural interfaces for paralyzed patients, and established neuromodulation companies with FDA-approved DBS and RNS systems treating movement disorders and epilepsy.
- First human implants: Neuralink and Paradromics achieved first human implants
- Clinical milestones: Synchron completed enrollment in COMMAND trial
- FDA acceleration: Multiple companies received Breakthrough Device designation
- Non-invasive growth: Consumer BCI for focus, meditation, and gaming expanding
- Clinical applications: Stroke rehabilitation becoming major non-invasive BCI use case
- Big Tech acquisitions: Meta acquired CTRL-Labs, Snap acquired NextMind for BCI capabilities
- Established DBS expansion: Medtronic, Abbott, and Boston Scientific continue advancing DBS technology with AI-assisted programming
- Neuralink
- Blackrock Neurotech
- Paradromics
- BrainGate
- Medtronic
- Abbott Laboratories
- Boston Scientific
- NeuroPace
- Synchron
- Precision Neuroscience
- Science Corp
- Motif Neurotech
- Forest Neurotech
- Neuralink Website
- Synchron Website
- Blackrock Neurotech Website
- Paradromics Website
- Precision Neuroscience Website
- Medtronic DBS Website
- Abbott Neuromodulation Website
- Boston Scientific DBS Website
- NeuroPace RNS Website
- Kernel Website
- Science Corp Website
- MindMaze Website
- g.tec Website
- EMOTIV Website
- Bitbrain Website
- Neurable Website
- Cognixion Website
- BrainCo Website
BCI technologies are being developed and applied to various neurodegenerative conditions:
- Neuralink: Targeting communication restoration for ALS patients through neural decoding of intended speech
- Blackrock Neurotech: Utah Array systems used in ALS research for motor function restoration
- Synchron: Stentrode for communication in late-stage ALS patients
- BrainGate: Clinical trials include ALS patients for cursor control and communication
- Medtronic: FDA-approved DBS systems for Parkinson's motor symptoms (tremor, rigidity)
- Abbott Laboratories: Infinity DBS system for Parkinson's disease treatment
- Boston Scientific: Vercise DBS with AI navigation for Parkinson's
- NeuroPace: RNS system — first FDA-approved closed-loop responsive neurostimulation for epilepsy
- MindMaze: FDA-cleared VR rehabilitation BCI for stroke motor recovery
- OpenBCI: Research platforms for stroke rehabilitation BCI studies
¶ Alzheimer's Disease and Memory Disorders
- Precision Neuroscience: Layer 7 cortical interface targeting memory restoration
- Motif Neurotech: Minimally invasive memory augmentation implant
- See also: Memory Prosthetic BCI for Alzheimer's Disease
¶ 2026 Device Updates and Clinical Trials
- N1 Chip: First human implant completed in 2025, demonstrating successful signal transmission from 1,024 electrodes
- PRIME Study: Human trials expanded to 10+ patients with quadriplegia, showing high-bandwidth motor intent decoding
- Telepathy: Consumer version announced for 2026, targeting mobility assistance
- Blindsight: FDA breakthrough device designation for visual cortex bypass, first prosthetic vision trials
- COMMAND Trial: Completed enrollment, FDA approval expected 2026
- Stentrode Gen 2: Increased electrode count (16→32), improved signal quality
- Switch Device: New wireless control hub for motor switching
- MoveAgain BCI: FDA approval for neural interface system (2025)
- Utah Array Gen 3: New flexible array with increased longevity
- Cerebus Interface: Updated for wireless operation
- Connexus Direct Data Interface: Entering human trials in 2026
- 65,000 electrode array: Highest channel count in development
- Layer 7 Cortical Interface: FDA breakthrough device, human trials planned 2026
- 1,024 channel system: High-resolution mapping capability